Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FS VH S/D 500 s-apr for Dura Defect Sealing in Posterior Fossa Surgery
NCT00681824Phase 2Completed
- Sponsor
- Baxter
- Start
- May 2008
- Primary completion
- Mar 2010
- Modality
- Implantable Devices, Transdermal Patches, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in cerebrospinal fluid leak comparing FS VH S/D 500 s-apr with Standard of Care (2 arms). Primary endpoint: Incidence of Cerebrospinal Fluid (CSF) Leakage Observed After Surgery at 33 days. Started May 2008; status: completed.
02
Drugs
tisseel
03
Conditions
cerebrospinal fluid leak
Beyond the preview
Go deeper on NCT00681824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00681824.